2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Bispecific Antibody Therapy, Non-Biological Therapies, Coagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thrombotic Disorders, VWD, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Pediatric
PAPER

4822 Exploring bleeding disorders with joint hypermobility: A qualitative study

Amanda Henderson, MD, MSc, Haowei Linda Sun, MD, MHSc, FRCPC2, Kelsey Uminski, MD, MPrecH, FRCPC3
1 University of Calgary, Calgary, Alberta, Canada
2 University of Alberta, Edmonton, Alberta, Canada
3 University of Calgary, Calgary, Alberta, Canada

Background: Joint hypermobility, characterized by an increased range of motion beyond expected norms, reflects underlying connective tissue laxity and may occur in isolation or as part of broader syndrome. A subset of individuals with joint hypermobility experience bleeding symptoms that prompt referral to hematology for assessment, placing hematologists in a key position to recognize hypermobility and initiate further evaluation. However, there is limited guidance regarding the assessment of joint hypermobility, diagnostic evaluation and hemostatic management of bleeding, and the role of hematologists in coordinating referral to other specialties for associated connective tissue manifestations. Consequently, clinical practice varies considerably, and multidisciplinary care pathways remain poorly standardized.

Aims: The purpose of this study was to explore current hematology practices in Canada for patients with bleeding disorders with joint hypermobility.

Methods: We conducted four semi-structured focus groups involving 11 hematologists (8 adult, 3 pediatric) from across Canada with expertise in bleeding disorders. Participants were recruited by email invitation distributed to all members of the Association of Hemophilia Clinic Directors of Canada. Discussions explored approaches to the assessment of joint hypermobility, diagnostic evaluation and hemostatic management of bleeding, referral practices, and multidisciplinary care coordination with other specialties. Two investigators independently coded transcripts and iteratively developed themes using Braun and Clarke’s reflexive thematic analysis.

Results: Participants had a range of 1 to 15 years of clinical experience and reported caring for an estimated average of approximately 120 patients with bleeding disorders with joint hypermobility each year across diverse adult and pediatric hematology practices. The typical clinical phenotype in this population consisted of females of reproductive age with abnormal uterine bleeding and mucocutaneous bleeding, alongside connective tissue manifestations including delayed wound healing. Participants described four overarching themes underlying their experience caring for this population. First, approaches to assessing hypermobility varied considerably across clinicians. Adult hematologists reported using assessment tools, such as the Beighton score, often in combination with patient history, family history, and physical examination to form an overall clinical impression for hypermobility. In contrast, pediatric hematologists described greater difficulty assessing hypermobility because of normal age-related joint laxity. Across both groups, participants reported limited confidence in evaluating hypermobility, citing a lack of formal education and standardized assessment approaches. Second, the diagnostic evaluation of bleeding in patients with joint hypermobility generally paralleled the established workup for bleeding disorder of unknown cause (BDUC), and management of acute bleeding, as well as perioperative and peripartum care, was largely consistent with established BDUC practices. Third, participants described uncertainty surrounding the management of non-hematologic manifestations of joint hypermobility, including chronic pain and indications for genetic evaluation, particularly regarding responsibility for ongoing care. Although multidisciplinary care was widely supported, limited access to specialist referral pathways was identified as a major barrier. Finally, participants emphasized the need for standardized approaches to hypermobility assessment, clearer referral pathways, and coordinated multidisciplinary models of care.

Conclusions: Hematologists play a key role in the recognition and management of patients with bleeding disorders with joint hypermobility; however, variation in assessment practices and limited referral pathways underscore the need for standardized evaluation frameworks and coordinated multidisciplinary care. By illuminating current practice patterns and gaps, this project will lay the groundwork for evidence-informed recommendations to improve patient care and better address the unique bleeding challenges in this population.

Amanda Henderson, MD, MSc: No relevant conflicts of interest to declare.